Aiolumab won initial approval in Canada for the treatment of pregnant women with type 2 diabetes and or with coeliac disease. This results from a retrospective multinational study of more than 1000 women who received a transcutaneous aiolumab injection by Inovio Pharmaceuticals Inc. of Vancouver Canada. These doses will be subject to the new U. S. Food and Drug Administrations fasting new drug directive which is accompanied by a mandatory phase 3 study which assesses diabetes outcomes of treated participants.

Walnuts a nut- and soluble fiber crop native to Madagascar and Madagascar were first used as medicine tablets in the early 1800s to treat rheumatism and also as nut- and grain-based supplements for diabetics and those taking blood pressure medicine drugs. Walnuts are well known for their antioxidant anti-inflammatory and anti-disease-preventing properties. Multivitamins containing walnuts have been shown to lower cholesterol and blood pressure and reduce triglycerides in people with and without type 2 diabetes and in individuals with coeliac disease. Therefore walnuts offer a potential new therapeutic opportunity for long-term clinical use in people with and without type 2 diabetes.

Prospective study looked at 1029 women treated with aiolumab during their first 4- to 12-month follow-up period (n 1076)5-aiolumab was given at 0. 5-1. 25 mgs per kgdayaiolumab at 0. 75-1. 25 mgs per kgdayaiolumab at 2. 15-1. 25 mgs per kgdayaiolumab at 2. 5-1. 25 mgs per kgday and aiolumab at 3 mgs per kgday.

Definitive test results were seen in 1 of 5 patients as well as in all others confirming the aim of the trial. Walnut had favorable glycemic and insulin responses with or without concurrent use of GLP-1 or T2 and antidiabetic drug-remodeling activity was measured in all patients reflecting the lipolytic potential of walnuts in significantly lower doses than any other available diabetes drugs.

Walnuts gained FDA approval on June 5 2020 and Inovio Pharmaceuticals (Ino) Ltd acquired Walnut Nutrition Inc. Ltd. acquired Walnut City Ltd. the designating Ino Foods as its corporate parent. The subsidiary and Ino Pharmaceuticals today withdrew their consent.

We are bringing this years trial event to our northeastern location that has a lot of eyes on the whether or not we see these drugs actually delivering their intended promise to the end patients said Seth Berkley MD PhD chief of the Section of Geriatrics and Geriatrics Research at Massachusetts General Hospital Boston.

Lead authors noted that the finding was disappointing since clinical trials of competing aiolumab drugs generally have been disappointing in many ways. While the Trials Global Network analysis is a positive step they nonetheless underscore the need to obtain much-needed follow-up data to truly understand success or failure of drug candidates for which there are minimal or variable.

About FenEm Science Inc.

FenEm Science Inc. develops new therapies based on findings and medical recommendations. The companys products are used around the world in academic medical centers pharmaceuticals and other medical settings; its clinical expertise has broadened to include finding new treatments for rare and curable diseases while its worldwide focus on discovery of medical synthetic analogs are enabling the development of novel medicines to treat a broad range of medical conditions.

FenEms clinical development pipeline comprises the research and development of compounds for many important conditions including:

Financial support for the research and development of new drugs is ongoing with management assistance from Pfizer Inc. and AstraZeneca PLC and owns several patents for compounds that are also being used clinically.